financetom
Business
financetom
/
Business
/
Stellantis Unit Reports 10% Decline in Q2 Sales
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stellantis Unit Reports 10% Decline in Q2 Sales
Jul 2, 2025 3:30 AM

06:08 AM EDT, 07/02/2025 (MT Newswires) -- Stellantis ( STLA ) FCA US unit reported Tuesday total sales of 309,973 vehicles, down 10% from a year earlier.

Jeff Kommor, head of the company's US sales, said sales of the Jeep and Ram brands continue to grow. For H1, both brands saw a 2% sales growth year-over-year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
G7, IEA Director to Hold Call Over Possible Joint Release of Petroleum From Reserves
G7, IEA Director to Hold Call Over Possible Joint Release of Petroleum From Reserves
Mar 11, 2026
04:46 AM EDT, 03/09/2026 (MT Newswires) -- The Group of Seven, or G7, finance ministers and the International Energy Agency executive director Fatih Birol will discuss on a call Monday over a possible joint release of petroleum from reserves coordinated by the IEA, the Financial Times reported Monday, citing unnamed sources familiar with the matter. The leaders will discuss the...
Starfighters Space Drops 5% Overnight As Fuel Cost Fears Offset Defense Demand Amid US-Iran War
Starfighters Space Drops 5% Overnight As Fuel Cost Fears Offset Defense Demand Amid US-Iran War
Mar 11, 2026
Starfighters Space Inc. ( FJET ) shares dropped nearly 5% in Sunday overnight trading as the aerospace sector grapples with the fallout of intensifying Middle East conflicts and a sharp rise in jet fuel prices. Fuel Costs Cloud Defense Rally Despite a massive 16.64% surge during Friday's market session, Starfighters Space ( FJET ) saw its momentum stall as investors...
Dyne Therapeutics Initiates Phase 3 Trial of Genetic Neuromuscular Disease Treatment
Dyne Therapeutics Initiates Phase 3 Trial of Genetic Neuromuscular Disease Treatment
Mar 11, 2026
04:30 AM EDT, 03/09/2026 (MT Newswires) -- Dyne Therapeutics ( DYN ) said over the weekend it started a phase 3 study of zeleciment basivarsen in participants with myotonic dystrophy type 1, a rare genetic neuromuscular disease. The 48-week study will enroll about 150 patients aged at least 16 years, who will be given 6.8 mg/kg of z-basivarsen or placebo...
Trump's China visit likely won't yield breakthrough, aims to maintain stability
Trump's China visit likely won't yield breakthrough, aims to maintain stability
Mar 11, 2026
(Corrects paragraph 12 to say Treasury Secretary Scott Bessent (not Bessent), giving his name and title on first reference.) By Laurie Chen and Michael Martina BEIJING/WASHINGTON, March 9 (Reuters) - A summit between U.S. President Donald Trump and China's Xi Jinping this month is unlikely to create room for even a limited reset of business and investment ties, five people...
Copyright 2023-2026 - www.financetom.com All Rights Reserved